Advanced Solid Tumors Clinical Trials

72 studies are recruiting for advanced solid tumors in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 2

1. A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.

   This study aims to evaluate the effects of rezatapopt on the pharmacokinetics of metformin, rosuvastatin, repaglinide, and midazolam in patients with advanced solid tumors harboring a TP53 Y220C mutation.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   HealthOne Denver, Denver, Colorado

   Locations

   5 in total

   Run by

   PMV Pharmaceuticals, Inc

   See if you can join NCT07372625 on ClinicalTrials.gov

2. A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

   This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent and in combination with chemotherapy administered intravenously in participants with advanced solid tumors that are antigen-rich.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   AdventHealth Celebration, Celebration, Florida

   Locations

   19 in total

   Run by

   Marengo Therapeutics, Inc.

   See if you can join NCT05592626 on ClinicalTrials.gov

3. A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors

   The purpose of this study is to assess the safety and tolerability of mRNA-4106 monotherapy and of mRNA-4200 in combination with checkpoint inhibitor therapy in participants with solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   START Midwest, Grand Rapids, Michigan

   Locations

   4 in total

   Run by

   ModernaTX, Inc.

   See if you can join NCT06880549 on ClinicalTrials.gov

4. A Study of PHN-012 in Patients With Advanced Solid Tumors

   This first-in-human study will evaluate safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of PHN-012, a novel antibody-drug conjugate (ADC), in patients with advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   PHN-012-001 Site, Los Angeles, California

   Locations

   26 in total

   Run by

   Pheon Therapeutics

   See if you can join NCT07127874 on ClinicalTrials.gov

5. Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

   The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RAS(ON) inhibitors in combination with ivonescimab in adults with advanced or metastatic solid tumors with a RAS mutation.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   USC Norris Comprehensive Cancer Center, Los Angeles, California

   Locations

   9 in total

   Run by

   Revolution Medicines, Inc.

   See if you can join NCT07397338 on ClinicalTrials.gov

6. Study of GS-2426 in Participants With Advanced Solid Tumors

   The goal of this clinical study is to learn more about the study drug GS-2426, and how safe and tolerable it is in participants with advanced methylthioadenosine phosphorylase (MTAP)-deleted solid tumors. The primary objective of this study is to evaluate the safety and tolerability of GS-2426 in p…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   START Midwest, Grand Rapids, Michigan

   Locations

   4 in total

   Run by

   Gilead Sciences

   See if you can join NCT07601243 on ClinicalTrials.gov

7. Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations

   A Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamic (PD), and preliminary antitumor activity of TYRA-430 in cancers with FGF/FGFR pathway aberrations, including locally advanced/metastatic hepatocellular carcinoma and other advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   USC Norris Comprehensive Cancer Center, Los Angeles, California

   Locations

   16 in total

   Run by

   Tyra Biosciences, Inc

   See if you can join NCT06915753 on ClinicalTrials.gov

8. A Study to Test the Safety and Tolerability of SBO-154 in Patients With Advanced Solid Tumors.

   This is a Phase 1 study of SBO-154 in patients with advanced cancers who are unable to tolerate or have not previously responded to standard therapy available in the country. The study involves multiple doses and takes place at several centers.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Honorhealth Research Institute, Scottsdale, Arizona

   Locations

   16 in total

   Run by

   Sun Pharma Advanced Research Company Limited

   See if you can join NCT07042100 on ClinicalTrials.gov

9. A Study to Evaluate Claudin 18.2-Directed ADC LCB02A in Advanced Solid Tumors

   This is a Phase 1/2 open label study consisting of dose escalation cohorts (Phase 1) followed by expansion cohorts (Phase 2). The Phase 1 dose escalation population includes subjects with advanced solid tumors that are refractory to standard of care therapy or for whom no standard of care options a…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   START New York - Long Island, Lake Success, New York

   Locations

   8 in total

   Run by

   LigaChem Biosciences, Inc.

   See if you can join NCT07460375 on ClinicalTrials.gov

10. A Study of ASP1002 in Adults for Treatment of Solid Tumors

    ASP1002 is being studied in people with tumors that have spread to nearby tissue (locally advanced) that cannot be removed by surgery (unresectable) or tumors that have spread to other parts of the body (metastatic). Claudin 4 protein, or CLDN4, is a protein found on tumors in different parts of th…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Yale University Cancer Center, New Haven, Connecticut

    Locations

    15 in total

    Run by

    Astellas Pharma Global Development, Inc.

    See if you can join NCT05719558 on ClinicalTrials.gov

11. A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors

    To evaluate the safety, tolerability, and DLTs and determine the MTD and/or RDE(s) of INCA33890 in participants with select advanced or metastatic solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    The Angeles Clinic and Research Institute, Los Angeles, California

    Locations

    39 in total

    Run by

    Incyte Corporation

    See if you can join NCT05836324 on ClinicalTrials.gov

12. A Clinical Trial to Evaluate the Safety, Tolerability and Clinical Efficacy of M3T01 Monotherapy and in Combination With Pembrolizumab and Other Systemic Therapies

    Phase 1 first-in-human, open-label, dose-escalation (3 + 3), dose-expansion clinical trial to evaluate the safety, tolerability and preliminary clinical efficacy of M3T01 (fully human IgG4/kappa monoclonal antibody targeting FasL) in subjects with metastatic or unresectable solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Providence Portland Cancer Institute - Franz Clinic, Portland, Oregon

    Run by

    Providence Health & Services

    See if you can join NCT06719362 on ClinicalTrials.gov

13. A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation

    The primary objective of the study is to evaluate the safety and tolerability of the continuation of sotorasib with or without panitumumab and/or other anti-cancer therapies in participants continuing to derive benefit in Amgen-sponsored protocols.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Florida Cancer Specialists - Fort Myers, Fort Myers, Florida

    Locations

    11 in total

    Run by

    Amgen

    See if you can join NCT07172919 on ClinicalTrials.gov

14. Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

    The primary goal of this study is to assess the safety and tolerability of mRNA-4359 administered alone and in combination with pembrolizumab or ipilimumab and nivolumab.

    Stage

    Phase 1

    Ages

    12 and older

    Site

    The Angeles Clinic and Research Institute, Los Angeles, California

    Locations

    39 in total

    Run by

    ModernaTX, Inc.

    See if you can join NCT05533697 on ClinicalTrials.gov

15. A Study of Safety, Tolerability and Preliminary Efficacy of NTS071 in Subjects With Advanced Solid Tumors Harboring a TP53 Y220C Mutation

    This study is to evaluate the safety, tolerability, PK, and preliminary efficacy of NTS071 in adults with TP53 Y220C-mutated solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Next Oncology, San Antonio, Texas

    Locations

    2 in total

    Run by

    Nutshell Therapeutics (Shanghai) Co., LTD.

    See if you can join NCT07060989 on ClinicalTrials.gov

16. Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors

    Phase 1/2, open-label study of ETX-636 in participants with advanced solid tumors

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Hoag Memorial Hospital Presbyterian, Newport Beach, California

    Locations

    15 in total

    Run by

    Ensem Therapeutics

    See if you can join NCT06993844 on ClinicalTrials.gov

17. A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations

    The purpose of this study is to characterize the safety and tolerability of ALTA3263 in adults with advanced solid tumors with KRAS mutations.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Research Site, Orlando, Florida

    Locations

    12 in total

    Run by

    Alterome Therapeutics, Inc.

    See if you can join NCT06835569 on ClinicalTrials.gov

18. An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 Alone or in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

    The primary objectives of this trial are to: * Characterize the safety and tolerability of TEV-56278 * Determine the Recommended Phase 2 Dose (RP2D) * Evaluate antitumor activity of TEV-56278 (Part 2 only) * Determine the safety and tolerability of TEV-56278 in combination with pembrolizumab * Dete…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Teva Investigational Site 12017, Los Angeles, California

    Locations

    12 in total

    Run by

    Teva Branded Pharmaceutical Products R&D LLC

    See if you can join NCT06480552 on ClinicalTrials.gov

19. Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

    This study is to evaluate the safety and tolerability of RMC-9805 as monotherapy and in combination with RMC-6236 in adults with KRAS G12D-mutant solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of California, Davis Comprehensive Cancer Center, Sacramento, California

    Locations

    17 in total

    Run by

    Revolution Medicines, Inc.

    See if you can join NCT06040541 on ClinicalTrials.gov

20. A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies

    A Phase 1/1B Study of ST-01156 in Patients with Advanced Solid Malignancies

    Stage

    Phase 1

    Ages

    16 and older

    Site

    The City of Hope National Medical Center, Duarte, California

    Locations

    6 in total

    Run by

    SEED Therapeutics, Inc.

    See if you can join NCT07197554 on ClinicalTrials.gov

21. A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORS

    The study (dose escalation/expansion) is being conducted to assess the safety and tolerability of SHR-A1904 in subjects with advanced solid tumors, and to determine maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D), to assess preliminary efficacy of SHR-A1904, pharmacokinetic (PK…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Dong-A University Hospital, Busan,

    Locations

    28 in total

    Run by

    Jiangsu HengRui Medicine Co., Ltd.

    See if you can join NCT05277168 on ClinicalTrials.gov

22. A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK201 in Participants With Advanced Solid Tumors

    This is a first-in-human (FIH), open-label, multicenter dose escalation and expansion study of ALK201. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and antitumor activity of ALK201 as a monotherapy in adult participants with Advanced Solid Tumors. The st…

    Stage

    Phase 1

    Ages

    18 to 75

    Site

    Denver Drug Development Unit, Denver, Colorado

    Locations

    38 in total

    Run by

    Shanghai Allink Biotherapeutics Co., Ltd.

    See if you can join NCT06656390 on ClinicalTrials.gov

23. Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

    Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    UC Irvine/Chao Family Comprehensive Cancer Center, Orange, California

    Locations

    21 in total

    Run by

    Revolution Medicines, Inc.

    See if you can join NCT05379985 on ClinicalTrials.gov

24. A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors

    A FIH dose escalation and dose expansion study to evaluate VVD-130037 in participants with advanced solid tumors as a single agent, and in combination with docetaxel, paclitaxel, or pembrolizumab.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Mayo Clinic Jacksonville, Jacksonville, Florida

    Locations

    26 in total

    Run by

    Vividion Therapeutics, Inc.

    See if you can join NCT05954312 on ClinicalTrials.gov

25. Study of DT-7012 as a Single Agent and in Combination With an Immune Checkpoint Inhibitor in Participants With Advanced Solid Tumors

    This is a phase 1/2, dose-escalation, clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of DT-7012 (an anti-CCR8 monoclonal antibody) as a single agent and in combination with an immune checkpoint inhibitor in adult participants with selected advan…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Macquarie University Clinical Trial Unit, North Ryde, New South Wales

    Locations

    9 in total

    Run by

    Domain Therapeutics Australia Pty Ltd

    See if you can join NCT06819735 on ClinicalTrials.gov